Dergiler / Eurasian Journal of Emergency Medicine / 2019 / Cilt: 18 - Sayı: 1

Warfarin Resistance: A Case Report

Sayfa
61–63
Yayın Tarihi
2022-10-11
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

In this paper, we discuss underlying genetic polymorphisms about warfarin resistance.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Warfarin is the most widely prescribed anticoagulant in the world.
📊
Temel Bulgular & Veri:Patients who need more than 15 mg per day should be considered warfarin-resistant.
💡
Sonuç & Katkı:In this paper, we discuss underlying genetic polymorphisms about warfarin resistance.
🔬Tür:Araştırma Makalesi
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Alan Parametreleri

Abstract

Warfarin is the most widely prescribed anticoagulant in the world. Patients who need more than 15 mg per day should be considered warfarin-resistant. Nearly 30 genes have been reported in association with warfarin pharmacogenetics but genetic polymorphisms in the genes encoding CYP2C9 and VKORC1 have been shown to act as the most important determinants of drug dosage requirements. The major enzyme responsible for the metabolism of S-warfarin, the more potent of warfarin’s two stereoisomers, is CYP2C9. Warfarin inhibits vitamin K epoxide reductase (VKOR). A 30-year-old woman was referred to our clinic for pulmonary embolism. She was treated with low molecular weight heparin. The warfarin dose was titrated up to 15 mg daily but after one week, the INR (international normalized ratio) was still subtherapeutic level at 1.8. In this paper, we discuss underlying genetic polymorphisms about warfarin resistance.

🔖

Bu Makaleye Atıf Yap

SILAN, F., ÖZDEMİR, Ö., GÖNLÜGÜR, U., GÖNLÜGÜR, T. (2022). Warfarin Resistance: A Case Report. Eurasian Journal of Emergency Medicine, Cilt: 18 - Sayı: 1, 61–63. https://ajindex.com/articles/508023

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (9)

  1. Pirmohamed M. Warfarin: almost 60 years old and still causing problems. Br J Clin Pharmacol. 2006;62:509-11.
  2. Hodroge A, Matagrin B, Moreau C, Fourel I, Hammed A, Benoit E, et al. VKORC1 mutations detected in patients resistant to vitamin K antagonists are not all associated with a resistant VKOR activity. J Thromb Haemost. 2012;10:2535-43.
  3. Altunbaş G, Ercan S, Davutoğlu V, Al B. Overview of warfarin treatment and answers to questions. The Journal of Academic Emergency Medicine. 2013;12:38-42.
  4. Sabol BJ, Basa RR, Wilkins CE. Malabsorption-associated warfarin resistance. Am J Health Syst Pharm. 2009;66:1548-53.
  5. Sattar A, Willman JE, Kolluri R. Possible warfarin resistance due to interaction with ascorbic acid: case report and literature review. Am J Health Syst Pharm. 2013;70:782-6.
  6. Pescetelli I, Genovesi E, Renda G, Di Renzo E, De Caterina R. Intracardiac thrombi during warfarin anticoagulation – A case report and a brief literature review. Cor et Vasa 2017;59:e277-81. Osinbowale O, Al Malki M, Schade A, Bartholomew JR. An algorithm for managing warfarin resistance. Cleve Clin J Med. 2009;76:724-30.
  7. Hosseini S, Kalantar E, Hosseini MS, Tabibian S, Shamsizadeh M, Dorgalaleh A. Genetic risk factors in patients with deep venous thrombosis, a retrospective case control study on Iranian population. Thromb J. 2015;13:35. Yildirim E, Erol K, Birdane A. Warfarin dose requirement in Turkish patients: the influences of patient characteristics and polymorphisms in CYP2C9, VKORC1 and factor VII. Hippokratia. 2014;18:319-27.
  8. Yardım O, Emektar E, Çevik Y, Çorbacıoğlu ŞK, Karabulut AE. Evaluation of the VKORC1 and CYP2C9 gene polymorphisms and their effects on the emergency complications in the patients using warfarin. Eurasian J Emerg Med. 2017;16:65-9.
  9. Yan X, Yang F, Zhou H, Zhang H, Liu J, Ma K, et al. Effects of VKORC1 genetic polymorphisms on warfarin maintenance dose requirement in a Chinese Han population. Med Sci Monit. 2015;21:3577-84. D’Andrea G, D’Ambrosio RL, Di Perna P, Chetta M, Santacroce R, Brancaccio V, et al. A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin. Blood. 2005;105:645-64.